Lv1
22 积分 2023-09-19 加入
Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases
5小时前
已完结
Combination of immunotherapy, radiotherapy and denosumab as the best approach even for NSCLC poor prognosis patients: a case report with strong response, prolonged survival and a review of literature
5小时前
已完结
Bone-targeting agents in major solid tumour metastases: a multinational cohort study
5小时前
已关闭
Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review
5小时前
已完结
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
21天前
已完结
Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation
27天前
已完结
Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions
29天前
已完结
ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance
29天前
已完结
Role of the MEK Inhibitor Trametinib in the Treatment of Metastatic Melanoma
1个月前
已关闭
Role of the MEK Inhibitor Trametinib in the Treatment of Metastatic Melanoma
1个月前
已关闭
皖公网安备34019202002308
